In 2015, the global hospital acquired infection treatment market was led by Abbott, Pfizer, Inc., Merck & Co., Inc., and Bayer AG. The market is currently contested by the growing count of generic drugs available in the world, owing to an ongoing upsurge of patent expirations. This could possibly be a negative effect for players trying to maintain favorable profit margins by selling branded drugs and treatments.
According to a research report released by Transparency Market Research, the global hospital acquired infection treatment market is highly fragmented and holds a medium level of competition for players of all sizes. Key players in the global hospital acquired infection treatment market are competing on the basis of treatment developments for multi-drug resistant pathogens and alternative molecule therapies. Simultaneously, the threat of new candidates in the over the future of the global hospital acquired infection treatment market is very high, owing to the growing demand for augmented therapeutics, notwithstanding the high entry barriers set by strict regulatory outlines and heavy in capital research and development efforts.
The global hospital acquired infection treatment market was valued at US$29.58 bn at the end of 2016 and is expected to expand at a CAGR of 2.7% within a forecast period from 2016 to 2024. By the end of 2024, this market is expected to reach an estimated US$36.61 bn.
Rising Geriatric Population Impels Demand for Hospital Acquired Infection Treatment in Advanced Economies
“There are multiple drivers that are currently supplementing the global hospital acquired infection treatment market. Of the many factors that currently lie in favor of the growth of the market, the leading one is the growing geriatric population. The elderly patients – owing to their lower physical immunity – are highly prone to common infections and even nosocomial infections. Therefore, the growing population of the geriatric is a serious factor that needs to be accounted for within the global hospital acquired infection treatment market,” states a TMR analyst.
Other factors motivating the growth of the global hospital acquired infection treatment market include the largely condition of healthcare organizations in emerging economies. A large percentage of the healthcare organizations in these regions hold a much lower level of hygiene, when compared to developed economies. They also possess a lower scope of infrastructure maintenance and sterilization techniques, which is giving rise to a very high rate of nosocomial infections and therefore, a very high demand in the global hospital acquired infection treatment market. Asia Pacific nations, for example, are currently leading the global hospital acquired infection treatment market in terms of demand based growth rate, thus attracting the more prominent players from the international competitive scenario.
Global Hospital Acquired Infection Treatment Market Disturbed by Growing Number of Multi-drug Resistant Bacteria Strains
A key limitation acting on the global hospital acquired infection treatment market at the moment is a stable rise in the rate of failures in treatment caused by the growing number of multi-drug resistant bacteria. With an increasing bacteria survival rate when exposed to drugs originally designed to eradicate them, the bacteria can end up developing a resistance to their effects. This is generating a lot of pressure on the healthcare industry in terms of developing alternative treatments.
“Leading operating entities in the global hospital acquired infection treatment market are likely to possess multiple pipeline drugs. Their successful approval can be a fillip for the overall global hospital acquired infection treatment market. The focus on nosocomial infections is increasing at a fast rate in all regions, including the emerging economies. This is encouraging players to enter a massively untapped market for patients from all income classes, further backed by government support. These avenues can prove to be fruitful for the global hospital acquired infection treatment market over the coming years,” adds the analyst.
The information presented in this review is based on a Transparency Market Research report, titled, “Hospital Acquired Infection Treatment Market (Infection Type - Urinary Tract Infections, Ventilator Associated Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infection, ENT Infections, Skin Infection, and Bone Infection; Treatment Type - Antibacterial, Antiviral, Antifungal Treatment, Antiparasitic, Antiprotozoal, and Anti-TB Treatment; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Store, and E-Commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
Key segments of the Global Hospital Acquired Infection Treatment Market
Global Hospital Acquired Infection Treatment Market, by Infection Type
- Urinary Tract Infections
- Ventilator Associated Pneumonia
- Surgical Site Infections
- Bloodstream Infections
- Other Hospital Infections (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)
Global Hospital Acquired Infection Treatment Market, by Treatment
- Antibacterial Treatment
- Antiviral Treatment
- Antifungal Treatment
- Amphotericin B
- Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)
Global Hospital Acquired Infection Treatment Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
Hospital Infection Therapeutics Market, by Geography
- North America
- Latin America
- Middle East and Africa
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453